{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026895","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.383725+00:00","generated_at":"2026-06-22T00:17:04.481519+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Isoray Q1 FY2023 revenue down 33% to $1.72M; net loss widens to $4.07M","bullets":["Revenue $1.72M vs $2.56M YoY; core prostate brachytherapy revenue fell 41%.","Net loss $4.07M ($0.03 per share) vs $2.24M ($0.02) in prior year.","Gross margin dropped to 24.1% from 40.1%; isotope supply disruption cited.","Cash and equivalents $54.1M with no long-term debt; stockholders' equity $57.7M.","Pending merger with Viewpoint Molecular Targeting noted; G&A rose 69% on deal costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026895","json":"https://secwatch.observer/filing/0001437749-22-026895.json","markdown":"https://secwatch.observer/filing/0001437749-22-026895.md","text":"https://secwatch.observer/filing/0001437749-22-026895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/0001437749-22-026895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/isr20221109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:17:04.481519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f96831441601b585a7717d0fed5959c3b6e2af7e","claim":"Perspective Therapeutics, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: revenue $1.72 million, net income $4.07 million or ($0.03) per basic and diluted share.","evidence_excerpt":"Revenue for the first quarter of fiscal 2023 decreased 33% to $1.72 million versus $2.56 million in the prior year comparable period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/0001437749-22-026895-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of fiscal 2023 ended September 30, 2022"},{"label":"Revenue","value":"$1.72 million"},{"label":"Net income","value":"$4.07 million or ($0.03) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}